Skip to main content
Clinical Trials/KCT0004724
KCT0004724Recruiting未知

The Effect of Lung-Conduction Exercise in Chronic Obstructive Pulmonary Disease (COPD): Randomized, Assessor-blind, Multicenter Pilot Trial

Dunsan Korean Medicine Hospital of Daejeon University0 sites54 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
54

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
40(Year) to 80(Year) (—)
Sex
All

Inclusion Criteria

  • Moderate and severe COPD patients who diagnosed by forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) <70 % and 30 % = FEV1 <80 %, aged 40 to 80, had complaints of difficulty in breathing at or above mMRC =2 points, voluntarily agreed to participate in this clinical trial is included.

Exclusion Criteria

  • Have serious respiratory illnesses other than COPD (e.g. lung cancer, pneumonia, active tuberculosis, tuberculosis pulmonary destruction, pneumonectomy, etc.); or with unstable cardiovascular disease (unstable angina, acute myocardial infarction, severe aortic stenosis, etc.) and severe untreated pulmonary hypertension; or with a history of acute deterioration within 2 weeks; or have a change in FEV1 or FVC of 12 % and 200 mL or more for 1 second before or after bronchodilator and attack of asthma; or with other illnesses that may cause death or disability during one year period (e.g. cancer, heart failure, coronary artery disease, cerebrovascular disease, kidney failure, diabetes with severe complications, uncontrolled high blood pressure, etc.); or have difficulty in walking (e.g., cerebrovascular disease, osteoarthritis, and other serious malnutrition); or persons who are unable to understand the consent form or continue the test due to mental retardation or intellectual problems; or pregnant or lactating women; or alcoholics or those with a history of substance abuse; or smoker; or participants who took medication of other clinical trials within 30 days prior to participation in this trial (based on written consent); or with a underlying disease judged by the investigators to be inappropriate for this trial.

Investigators

Sponsor
Dunsan Korean Medicine Hospital of Daejeon University

Similar Trials